Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: A pilot study of 21 patients

Midori Hasegawa, Atsushi Ohashi, Nao Kabutan, Saori Hiramatsu, Masao Kato, Kazutaka Murakami, Makoto Tomita, Kunihiro Nabeshima, Yoshiyuki Hiki, Satoshi Sugiyama

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Twenty-one patients with myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis were treated using cytapheresis. Of these, 17 were treated for glomerulonephritis and four were treated for pulmonary hemorrhage. The overall survival rate was 85.7% with a follow-up duration of 24.0 ± 13.8 months. In the 17 patients with MPO-ANCA-associated glomerulonephritis, pretreatment creatinine was 3.2 ± 1.6 mg/dL, and renal function recovered in 76.5%. Pulmonary hemorrhage was ameliorated in all four patients. Abdominal pain occurred in three of the 21 patients but symptoms resolved soon after the cytapheresis procedure was completed. No other adverse effects occurred during cytapheresis. From these results, cytapheresis can be considered a safe and effective treatment for MPO-ANCA-associated vasculitis. As for the mechanism of its action, soluble tumor necrosis factor receptor 1 (sTNFR), sTNFR2 and interleukin 1 receptor antagonist were elevated soon after cytapheresis and those levels 2 h after the cytapheresis procedure were higher than before the procedure in some cases. These elevations might be related to the efficacy of cytapheresis.

Original languageEnglish
Pages (from-to)412-418
Number of pages7
JournalTherapeutic Apheresis and Dialysis
Volume10
Issue number5
DOIs
Publication statusPublished - 01-10-2006

Fingerprint

Cytapheresis
Vasculitis
Autoantibodies
Peroxidase
Glomerulonephritis
Therapeutics
Hemorrhage
Lung
Interleukin-1 Receptors
Tumor Necrosis Factor Receptors
Abdominal Pain
Creatinine
Survival Rate
Kidney

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

Hasegawa, Midori ; Ohashi, Atsushi ; Kabutan, Nao ; Hiramatsu, Saori ; Kato, Masao ; Murakami, Kazutaka ; Tomita, Makoto ; Nabeshima, Kunihiro ; Hiki, Yoshiyuki ; Sugiyama, Satoshi. / Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis : A pilot study of 21 patients. In: Therapeutic Apheresis and Dialysis. 2006 ; Vol. 10, No. 5. pp. 412-418.
@article{9ea14aa729e54a4a84e2bcb673616663,
title = "Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: A pilot study of 21 patients",
abstract = "Twenty-one patients with myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis were treated using cytapheresis. Of these, 17 were treated for glomerulonephritis and four were treated for pulmonary hemorrhage. The overall survival rate was 85.7{\%} with a follow-up duration of 24.0 ± 13.8 months. In the 17 patients with MPO-ANCA-associated glomerulonephritis, pretreatment creatinine was 3.2 ± 1.6 mg/dL, and renal function recovered in 76.5{\%}. Pulmonary hemorrhage was ameliorated in all four patients. Abdominal pain occurred in three of the 21 patients but symptoms resolved soon after the cytapheresis procedure was completed. No other adverse effects occurred during cytapheresis. From these results, cytapheresis can be considered a safe and effective treatment for MPO-ANCA-associated vasculitis. As for the mechanism of its action, soluble tumor necrosis factor receptor 1 (sTNFR), sTNFR2 and interleukin 1 receptor antagonist were elevated soon after cytapheresis and those levels 2 h after the cytapheresis procedure were higher than before the procedure in some cases. These elevations might be related to the efficacy of cytapheresis.",
author = "Midori Hasegawa and Atsushi Ohashi and Nao Kabutan and Saori Hiramatsu and Masao Kato and Kazutaka Murakami and Makoto Tomita and Kunihiro Nabeshima and Yoshiyuki Hiki and Satoshi Sugiyama",
year = "2006",
month = "10",
day = "1",
doi = "10.1111/j.1744-9987.2006.00404.x",
language = "English",
volume = "10",
pages = "412--418",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "5",

}

Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis : A pilot study of 21 patients. / Hasegawa, Midori; Ohashi, Atsushi; Kabutan, Nao; Hiramatsu, Saori; Kato, Masao; Murakami, Kazutaka; Tomita, Makoto; Nabeshima, Kunihiro; Hiki, Yoshiyuki; Sugiyama, Satoshi.

In: Therapeutic Apheresis and Dialysis, Vol. 10, No. 5, 01.10.2006, p. 412-418.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis

T2 - A pilot study of 21 patients

AU - Hasegawa, Midori

AU - Ohashi, Atsushi

AU - Kabutan, Nao

AU - Hiramatsu, Saori

AU - Kato, Masao

AU - Murakami, Kazutaka

AU - Tomita, Makoto

AU - Nabeshima, Kunihiro

AU - Hiki, Yoshiyuki

AU - Sugiyama, Satoshi

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Twenty-one patients with myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis were treated using cytapheresis. Of these, 17 were treated for glomerulonephritis and four were treated for pulmonary hemorrhage. The overall survival rate was 85.7% with a follow-up duration of 24.0 ± 13.8 months. In the 17 patients with MPO-ANCA-associated glomerulonephritis, pretreatment creatinine was 3.2 ± 1.6 mg/dL, and renal function recovered in 76.5%. Pulmonary hemorrhage was ameliorated in all four patients. Abdominal pain occurred in three of the 21 patients but symptoms resolved soon after the cytapheresis procedure was completed. No other adverse effects occurred during cytapheresis. From these results, cytapheresis can be considered a safe and effective treatment for MPO-ANCA-associated vasculitis. As for the mechanism of its action, soluble tumor necrosis factor receptor 1 (sTNFR), sTNFR2 and interleukin 1 receptor antagonist were elevated soon after cytapheresis and those levels 2 h after the cytapheresis procedure were higher than before the procedure in some cases. These elevations might be related to the efficacy of cytapheresis.

AB - Twenty-one patients with myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis were treated using cytapheresis. Of these, 17 were treated for glomerulonephritis and four were treated for pulmonary hemorrhage. The overall survival rate was 85.7% with a follow-up duration of 24.0 ± 13.8 months. In the 17 patients with MPO-ANCA-associated glomerulonephritis, pretreatment creatinine was 3.2 ± 1.6 mg/dL, and renal function recovered in 76.5%. Pulmonary hemorrhage was ameliorated in all four patients. Abdominal pain occurred in three of the 21 patients but symptoms resolved soon after the cytapheresis procedure was completed. No other adverse effects occurred during cytapheresis. From these results, cytapheresis can be considered a safe and effective treatment for MPO-ANCA-associated vasculitis. As for the mechanism of its action, soluble tumor necrosis factor receptor 1 (sTNFR), sTNFR2 and interleukin 1 receptor antagonist were elevated soon after cytapheresis and those levels 2 h after the cytapheresis procedure were higher than before the procedure in some cases. These elevations might be related to the efficacy of cytapheresis.

UR - http://www.scopus.com/inward/record.url?scp=33750442906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750442906&partnerID=8YFLogxK

U2 - 10.1111/j.1744-9987.2006.00404.x

DO - 10.1111/j.1744-9987.2006.00404.x

M3 - Article

C2 - 17096695

AN - SCOPUS:33750442906

VL - 10

SP - 412

EP - 418

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 5

ER -